Publications by authors named "Geru A"
Article Synopsis
- - The study aimed to determine how long it takes for intensive lipid-lowering therapy to reduce major adverse cardiovascular events (MACE) in people with established cardiovascular disease (CVD), particularly before and after 2010 when new treatments like PCSK9 inhibitors and ezetimibe were introduced.
- - Researchers reviewed seven randomized controlled trials involving over 92,000 adults and found that it takes about 19.6 months of intensive therapy to prevent one MACE per 100 patients, with variations based on the treatment used.
- - Results showed that before 2010, high-intensity statin therapy required a TTB of 15.2 months, while PCSK9i and ezetimibe therapies had longer TTB
Article Synopsis
- Researchers studied 472 patients with left ventricular thrombus (LVT) to identify unique clinical profiles using cluster analysis.
- They found two distinct groups: one made up of younger patients with fewer risk factors linked primarily to recent heart attacks, and another older group with more comorbidities related to ischemic cardiomyopathy.
- The study revealed that the second group had a lower chance of LVT resolution and a higher risk of mortality, highlighting the importance of tailored treatment approaches for different patient profiles.
Article Synopsis
- Intracranial hemorrhage (ICH) poses a serious risk for patients on Direct Oral Anticoagulants (DOACs), and existing risk scores are not effective in predicting this risk.
- A study developed a predictive model using data from 24,794 DOAC-treated patients, identifying six key risk factors through advanced modeling techniques like XGBoost.
- The resulting model showed better predictive performance than current DOAC risk scores, suggesting it can be a helpful tool for assessing ICH risk in these patients.
Background: Low-dose colchicine has been shown to lower major adverse cardiovascular events (MACE) among those with cardiovascular disease (CVD). It remains unclear how long a CVD patient needs to live to potentially benefit from colchicine. Our study aimed to determine the time to benefit (TTB) of colchicine in individuals with CVD.
View Article and Find Full Text PDFPurpose: Thrombus aspiration in ST-elevation myocardial infarction (STEMI) with high thrombus burden did not improve clinical outcomes. The clinical efficacy of the bailout use of platelet glycoprotein IIb/IIIa inhibitors (GPIs) in this clinical scenario remains unknown.
Methods: We assessed associations between GPI use and in-hospital major bleeds, ischemic events, and mortality among STEMI patients treated with percutaneous coronary intervention (PCI) and thrombus aspiration in a nationwide acute coronary syndrome registry (the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome project).
Purpose: It is unknown if acute coronary syndrome (ACS) patients presenting with advanced Killip class (III/IV) would benefit from early statin therapy. Therefore, we aimed to explore the relationship between statin therapy within the first 24 h of medical contact and in-hospital outcomes in this patient population in a nationwide registry.
Method: In the Improving Care for Cardiovascular Disease in China-ACS project, among ACS patients presenting with Killip class III/IV, we performed the following three analyses: (i) the associations between early statin therapy and risks for in-hospital mortality and ischaemic events; (ii) the dose effect of statins on mortality and (iii) the interaction between low-density lipoprotein cholesterol (LDL-C) levels and statins on mortality.
Purpose: Previous reports demonstrated a bleeding avoidance potential of angiotensin converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) and β-blocker. It remains unclear whether early guideline-directed medical therapy [GDMT, i.e.
View Article and Find Full Text PDFPatients with ST-segment elevation myocardial infarction (STEMI) who are treated by primary percutaneous coronary intervention (PPCI) have an increased risk of developing contrast-induced nephropathy (CIN) when compared with patients undergoing elective percutaneous coronary intervention (PCI). However, CIN prevention measures are less frequently applied in PPCI than in elective PCI. At present, no preventive strategy has been recommended by the current guidelines for patients with STEMI undergoing PPCI.
View Article and Find Full Text PDF